GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

GenSight Biologics S.A.

GenSight Biologics  is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

msh id	COM:GENSIGHT-BIOLOGICS
symbol	SIGHT
name	GenSight Biologics S.A.
homepage url	https://www.gensight-biologics.com
country	FR
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	16
crunchbase url	-
linkedin url	-
founders	-

market cap	33.54M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	32.1
growth score 28	51.99
growth score 90	47.29
growth score 365	47.57

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.13
growth cost of revenue	-
growth depreciation and amortization	-1
growth ebitda	-0.19
growth ebitda ratio	-0.02
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	0.16
growth gross profit ratio	-

COM:GENSIGHT-BIOLOGICS

GenSight Biologics S.A.

Last Close

0.31

21/11 16:35

Market Cap

31.04M

Beta: -

Volume Today

175.72K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	37.14M
cost of revenue	37.14M
depreciation and amortization	-
ebitda	-33.9M
ebitda ratio	-10.47
eps	-0.58
eps diluted	-0.58
operating expenses	37.14M
operating income	-33.9M
operating income ratio	-10.47

accounts receivables	-1.08K
capital expenditure	-10.8K
cash at beginning of period	11.45M
cash at end of period	2.3M
inventory	-
working capital ttm	8.31M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-